A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Summary

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

Timeline

Start

2022-06-13

Primary completion

2023-03-23

Completion

2023-04-10

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs JNJ-77242113 10 mg QD; p =0.002; Cochran-Mantel-Haenszel NCT05357755 ↗

registry analysis (superiority test); Placebo vs JNJ-77242113 50 mg QD; p <0.001; Cochran-Mantel-Haenszel NCT05357755 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotrokinra	Peptide	—	Oral

Indications